Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Bio-Plexus Announces Financing.


VERNON, Conn.--(BW HealthWire)--April 27, 1999--

Bio-Plexus today announced a private placement convertible debenture Convertible Debenture

Any type of debenture that can be converted into some other security.

Notes:
For example, a convertible bond can be converted into stock.
 financing of up to $4,500,000. "This funding will help enable us to capitalize on Cap´i`tal`ize on`   

v. t. 1. To turn (an opportunity) to one's advantage; to take advantage of (a situation); to profit from; as, to capitalize on an opponent's mistakes s>.
 the exciting growth opportunities available today as the market converts to safety medical products," said Richard L. Higgins, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  of Bio-Plexus.

"Right now only about 10% of all needle markets are safety devices. But we expect these figures to change as additional states join Maryland, Tennessee and California in passing legislation mandating the use of safety needles," Higgins added. Bills continue to be introduced in other states, and Federal OSHA OSHA
n.
Occupational Safety and Health Administration, a branch of the US Department of Labor responsible for establishing and enforcing safety and health standards in the workplace.
 is also considering more stringent regulations to ensure the use of safe needles.

Bio-Plexus, Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
:BPLX), is a designer, developer, manufacturer, and marketer of safety medical products and needles under the PUNCTUR-GUARD(R) and DROP-IT(R) brand names. The company holds U.S. and international patents on safety medical devices designed to reduce the incidence of accidental needlesticks among healthcare workers. Accidental needlesticks number more than one million per year in the United States and can result in the transmission of deadly diseases including HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States.  and hepatitis.

NOTE: THIS PRESS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS, WHICH ARE SUBJECT TO RISKS AND UNCERTAINTIES. THE ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE DESCRIBED IN ANY SUCH FORWARD-LOOKING STATEMENT AS A RESULT OF FACTORS DESCRIBED FROM TIME TO TIME IN THE COMPANY'S PERIODIC REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION OR DISCUSSED IN OTHER PRESS RELEASES ISSUED BY THE COMPANY.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Apr 28, 1999
Words:251
Previous Article:FileTek Signs Comprehensive Letter of Intent to Give StorageTek Exclusive Rights to Sell StorHouse/RM Data Warehouse Software in Major European...
Next Article:American States Water Company Shareholders Elect Directors.
Topics:



Related Articles
Bio-Plexus Reports 3rd Quarter Results.
Bio-Plexus Announces New Terms and Year-End Results.
Bio-Plexus Reports 3Rd Quarter Earnings.
Bio-Plexus Reports 1st Quarter Results.
Bio-Plexus Names New CEO Launches Next Phase of Strategic Plan With Capital Infusion.
Bio-Plexus Recognized as One of State's Fastest Growing Technology Companies.
Bio-Plexus Positions for Growth.
Bio-Plexus to Adjourn Special Meeting.
Special Meeting Set - Move Toward Safety Grows.
Bio-Plexus Wins Shareholder Approval of Financing.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles